These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. Singer JW; Narahara KA; Ritchie JL; Hamilton GW; Kennedy JW Cancer Treat Rep; 1978 Jun; 62(6):945-8. PubMed ID: 667873 [TBL] [Abstract][Full Text] [Related]
4. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572 [TBL] [Abstract][Full Text] [Related]
5. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
6. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin. Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995 [TBL] [Abstract][Full Text] [Related]
7. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients. Hutchinson RJ; Bailey C; Wood D; Donaldson MH Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high-dose, short-term protocol]. D'Alto M; Maurea S; Basso A; Polverino W; Bianchi U; Bonelli A; Silvestro P; Salvatore M; Chiariello M Cardiologia; 1997 Jun; 42(6):611-8. PubMed ID: 9289377 [TBL] [Abstract][Full Text] [Related]
10. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. Warrell RP; Arlin ZA; Kempin SJ; Young CW Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022 [TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity. Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365 [TBL] [Abstract][Full Text] [Related]
14. Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. Bertelli G; Amoroso D; Pronzato P; Rosso R Anticancer Res; 1988; 8(4):645-6. PubMed ID: 3178154 [TBL] [Abstract][Full Text] [Related]
15. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Bristow MR; Billingham ME; Mason JW; Daniels JR Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861 [TBL] [Abstract][Full Text] [Related]
16. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. De Leonardis V; Neri B; Bacalli S; Cinelli P Int J Clin Pharmacol Res; 1985; 5(2):137-42. PubMed ID: 3860480 [TBL] [Abstract][Full Text] [Related]
17. [Biventricular heart failure in patient treated with anthracycline in childhood: myocardial dysfunction is not always the cause]. Iarussi D; Martino V; Iacono C; Indolfi P; Muto R; Calabrò R Ital Heart J Suppl; 2004 Apr; 5(4):294-7. PubMed ID: 15185468 [TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Platel D; Bonoron-Adèle S; Dix RK; Robert J Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608 [TBL] [Abstract][Full Text] [Related]
19. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. Li W; Xu B; Xu J; Wu XL Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757 [TBL] [Abstract][Full Text] [Related]
20. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography. Gillings S; Johnson J; Fulmer A; Hauck M Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]